<DOC>
	<DOCNO>NCT02008682</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial investigate efficacy safety liraglutide compare sitagliptin , add-on metformin Chinese subject type 2 diabetes inadequately control metformin monotherapy . Eligible subject continue metformin background treatment trial .</brief_summary>
	<brief_title>The Efficacy Safety Liraglutide Compared Sitagliptin , Both Combination With Metformin Chinese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Male female , age least 18 year 80 year time signing informed consent Subjects diagnose type 2 diabetes mellitus treat metformin monotherapy stable dose least 1500 mg daily maximum tolerate dose equal 1000 mg daily least 60 day prior screen HbA1c 7.010.0 % ( inclusive ) Body mass index equal 45.0 kg/m^2 Treatment glucose lower agent ( ) state inclusion criterion period 60 day prior screen . An exception shortterm treatment ( equal 7 day total ) insulin connection intercurrent illness History chronic pancreatitis idiopathic acute pancreatitis Any chronic disorder severe disease discretion investigator might jeopardise subject 's safety compliance protocol Screening calcitonin value equal 50 ng/l Personal family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome type 2 Diagnosis malignant neoplasm previous 5 year ( except basal cell skin cancer squamous cell skin cancer ) Any contraindication liraglutide , sitagliptin metformin accord local labelling</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>